argenx (ARGX) Stock Price, News & Analysis

Company Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Key Stats

• Today's Range: $605.32 to $618.40
• 50-Day Range: $519.76 to $605.92
• 52-Week Range: $327.73 to $618.40
• Volume: 313,493 shs
• Average Volume: 310,355 shs
• Market Capitalization: $36.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $630.42
• Consensus Rating: Moderate Buy

argenx Stock Analysis - MarketRank™

argenx scored higher than 51% of companies evaluated by MarketBeat, and ranked 546th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

argenx has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

argenx has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 293.18%

Earnings Growth

Earnings for argenx are expected to grow by 293.18% in the coming year, from $2.20 to $8.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenx is -688.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenx is -688.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

argenx has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.82% of the outstanding shares of argenx have been sold short.

Short Interest Ratio / Days to Cover

argenx has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in argenx has recently decreased by 4.49%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenx does not currently pay a dividend.

Dividend Growth

argenx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.82% of the outstanding shares of argenx have been sold short.

Short Interest Ratio / Days to Cover

argenx has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in argenx has recently decreased by 4.49%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.33

News Sentiment

argenx has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for argenx this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

12 people have added argenx to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.43% of the stock of argenx is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARGX Stock Analysis - Frequently Asked Questions

How have ARGX shares performed this year?

argenx's stock was trading at $380.43 at the start of the year. Since then, ARGX shares have increased by 59.2% and is now trading at $605.66.
View the best growth stocks for 2024 here.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its earnings results on Thursday, October, 31st. The company reported $1.39 EPS for the quarter, beating the consensus estimate of $0.10 by $1.29. The firm earned $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative trailing twelve-month return on equity of 1.45% and a negative net margin of 2.11%.

When did argenx IPO?

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

Top institutional shareholders of argenx include FMR LLC (8.02%), Janus Henderson Group PLC (4.15%), Bellevue Group AG (1.06%) and Wellington Management Group LLP (0.81%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that argenx investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 11/26/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ARGX
• CUSIP: N/A
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 1,148
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $630.42
• High Stock Price Target: $715.00
• Low Stock Price Target: $500.00
• Potential Upside/Downside: +4.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 23 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 275.30
• P/E Growth: N/A
• Net Income: $-295,050,000.00
• Net Margins: -2.11%
• Pretax Margin: N/A
• Return on Equity: -1.45%
• Return on Assets: -1.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.53
• Quick Ratio: 7.88

Sales & Book Value

• Annual Sales: $1.27 billion
• Price / Sales: 28.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $69.22 per share
• Price / Book: 8.75

Miscellaneous

• Outstanding Shares: 60,370,000
• Free Float: 58,901,000
• Market Cap: $36.56 billion
• Optionable: Optionable
• Beta: 0.61